The company has submitted a 510(k) application to the US FDA for its wearable disposable insulin pump EOPatch that was launched in Korea in Apr 2021, EU in Sept 2022 & UAE’s approval in the same month while in Indonesia in Oct 2022
The company is currently in talks with the US distributors & plans to sign a distribution agreement in H1’23. EOPatch 3.0 is expected to be available in 2024 & was evaluated in multiple tests with samples that have a 3ml reservoir & can work for 7 days using EOFlow’s pumping technology
The wearable integrated artificial pancreas solution received BTD in the US which is a wearable disposable device that features a glucose monitoring sensor, an insulin pump & an integrated automated insulin delivery algorithm
Ref: PRNewswire | Image: EOFlow
Related News:- Sosei Heptares Entered into a Drug Discovery Collaboration with Eli Lilly to Develop and Commercialize Small Molecules for Diabetes and Metabolic Diseases
